

POSITIVE RESULTS IN KAISER PERMANENTE USER PROGRAMME

Cancer diagnostics company Pacific Edge (NZX: PEB) has advised that it has successfully completed its analysis of the data from the large scale Kaiser Permanente (Kaiser) User Programme with positive and compelling findings.

The performance of Pacific Edge's Cxbladder Triage test was evaluated in a large, blinded study (User Programme) on consenting Kaiser patients, with findings equivalent to the previously published performance for Cxbladder Triage. Kaiser is currently completing its own analysis of the data, with the joint analysis to be submitted for scientific and clinical publication.

Cxbladder Triage is designed to rule out patients who have a low risk of having urothelial cancer (bladder cancer). A previously published study on Cxbladder Triage's performance, in the BioMed Central (BMC) Urology Journal in April 2015, showed a sensitivity of 95.1% and a Negative Predictive Value of 98.5%, meaning that Cxbladder Triage accurately identified those patients that had a low probability of having bladder cancer and therefore did not require a full workup for bladder cancer.

CEO and Managing Director of Pacific Edge, David Darling, said: "The positive confirmation and validation of the performance of Cxbladder Triage in the Kaiser clinical setting, where the diagnosis was blinded to us until the end of the study, is a direct reflection of the quality of the Cxbladder Triage test.

"Our analysis further validates Cxbladder's clinical utility in haematuria and bladder cancer management and supports our goal to create diagnostic tests that are highly accurate, non-invasive, cost effective and simple to use. Cxbladder Triage can potentially save many patients from undergoing an expensive and invasive investigation for bladder cancer."

The purpose of the User Programme was to allow Kaiser to assess the use of Cxbladder Triage in Kaiser's own clinical settings, to effectively and accurately rule out those patients who present with haematuria¹ who have a low probability of having bladder cancer and therefore may not need a full clinical workup.

David Darling commented: "Kaiser Permanente is one of America's largest not-for-profit health care providers, with a strong vision for improving patient outcomes. We are looking forward to working with Kaiser to scientifically publish the detailed results and negotiate a commercial relationship".

ENDS

¹ blood in the urine and an indicator of bladder cancer

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacifedge.co.nz www.pacifedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to www.cxbladder.com for more information.